RU2019101849A - Композиции и способы лечения синдрома раздраженного кишечника - Google Patents

Композиции и способы лечения синдрома раздраженного кишечника Download PDF

Info

Publication number
RU2019101849A
RU2019101849A RU2019101849A RU2019101849A RU2019101849A RU 2019101849 A RU2019101849 A RU 2019101849A RU 2019101849 A RU2019101849 A RU 2019101849A RU 2019101849 A RU2019101849 A RU 2019101849A RU 2019101849 A RU2019101849 A RU 2019101849A
Authority
RU
Russia
Prior art keywords
disease
administration
independently
compound
independently represents
Prior art date
Application number
RU2019101849A
Other languages
English (en)
Other versions
RU2019101849A3 (ru
RU2751770C2 (ru
Inventor
Махеш КАНДУЛА
Original Assignee
Селликс Био Прайвет Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селликс Био Прайвет Лимитед filed Critical Селликс Био Прайвет Лимитед
Publication of RU2019101849A publication Critical patent/RU2019101849A/ru
Publication of RU2019101849A3 publication Critical patent/RU2019101849A3/ru
Application granted granted Critical
Publication of RU2751770C2 publication Critical patent/RU2751770C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (62)

1. Соединение формулы I:
Figure 00000001
и его фармацевтически приемлемые соли, гидраты, сольваты, пролекарства, энантиомеры и стереоизомеры;
где,
каждый из R1, R3, R5 независимо представляет собой Н, D, СН3СО-, СН3, CD3CO-, отсутствует,
Figure 00000002
Figure 00000003
каждый из R2, R4, R6 независимо представляет собой
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
n независимо равен 1, 2, 3, 4 или 5;
а независимо равен 2, 3 или 7;
каждый b независимо равен 3, 5 или 6;
е независимо равен 1, 2 или 6;
каждый c и d независимо представляет собой Н, D, -ОН, -OD, C1-С6-алкил, -NH2 или -СОСН3.
2. Соединение формулы II:
Figure 00000013
Figure 00000014
и его фармацевтически приемлемые соли, гидраты, сольваты, пролекарства, энантиомеры и стереоизомеры;
где
каждый из R1, R3 независимо представляет собой Н, D, СН3СО-, СН3, CD3CO-, отсутствует, представляет собой
Figure 00000015
Figure 00000016
каждый из R2, R4 независимо представляет собой D, OD,
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
n независимо равен 1, 2, 3, 4 или 5;
а независимо равен 2, 3 или 7;
каждый b независимо равен 3, 5 или 6;
е независимо равен 1, 2 или 6;
каждый c и d независимо представляет собой Н, D, -ОН, -OD, C1-С6-алкил, -NH2 или -СОСН3;
при условии присутствия
Figure 00000027
каждый i независимо представляет собой
Figure 00000028
3. Фармацевтическая композиция, содержащая соединение по п. 1 и фармацевтически приемлемый носитель.
4. Фармацевтическая композиция, содержащая соединение по п. 2 и фармацевтически приемлемый носитель.
5. Фармацевтическая композиция по п. 3, приготовленная для лечения основной причины заболевания путем введения эффективного количества композиции нуждающемуся в этом пациенту перорально, с отсроченным или замедленным высвобождением, путем трансмукозального введения, введения в виде сиропа, местного, парентерального введения, инъекции, подкожного введения, введения в виде перорального раствора, ректального введения, буккального введения или трансдермального введения.
6. Фармацевтическая композиция по п. 4, приготовленная для лечения основной причины заболевания путем введения эффективного количества композиции нуждающемуся в этом пациенту перорально, с отсроченным или замедленным высвобождением, путем трансмукозального введения, введения в виде сиропа, местного, парентерального введения, инъекции, подкожного введения, введения в виде перорального раствора, ректального введения, буккального введения или трансдермального введения.
7. Соединения и композиции по п. 5, приготовленные для лечения основной причины заболевания, например, воспалительного заболевания кишечника, болезни Крона, синдрома раздраженного кишечника, целиакии, малабсорбации фруктозы, легкой инфекции, паразитарных инфекций, таких как лямблиоз, малабсорбации желчных кислот, функционального хронического запора, избыточного бактериального роста в тонком кишечнике и хронической функциональной боли в животе.
8. Соединения и композиции по п. 6, приготовленные для лечения основной причины заболевания, например, воспалительного заболевания кишечника, болезни Крона, синдрома раздраженного кишечника, целиакии, малабсорбации фруктозы, легких инфекций, паразитарных инфекций, таких как лямблиоз, малабсорбации желчных кислот, функционального хронического запора, избыточного бактериального роста в тонком кишечнике и хронической функциональной боли в животе.
9. Способ лечения по меньшей мере одного из заболеваний желудочно-кишечного тракта, иммуноопосредованного заболевания и воспалительного заболевания, включающий:
введение пациенту, страдающему от по меньшей мере одного из заболеваний желудочно-кишечного тракта, иммунооопосредованного заболевания и воспалительного заболевания, соединения Формулы I, включающего
Figure 00000029
10. Способ лечения по меньшей мере одного из заболеваний желудочно-кишечного тракта, иммуноопосредованного заболевания и воспалительного заболевания, включающий:
введение пациенту, страдающему от по меньшей мере одного из заболеваний желудочно-кишечного тракта, иммуноопосредованного заболевания и воспалительного заболевания, соединения формулы I, включающего
Figure 00000030
RU2019101849A 2016-08-11 2017-04-19 Композиции и способы лечения синдрома раздраженного кишечника RU2751770C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641027529 2016-08-11
IN201641027529 2016-08-11
PCT/IB2017/052233 WO2018029545A1 (en) 2016-08-11 2017-04-19 Compositions and methods for the treatment of irritable bowel syndrome

Publications (3)

Publication Number Publication Date
RU2019101849A true RU2019101849A (ru) 2020-09-11
RU2019101849A3 RU2019101849A3 (ru) 2020-09-11
RU2751770C2 RU2751770C2 (ru) 2021-07-16

Family

ID=61163212

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019101849A RU2751770C2 (ru) 2016-08-11 2017-04-19 Композиции и способы лечения синдрома раздраженного кишечника

Country Status (14)

Country Link
US (2) US11078154B2 (ru)
EP (1) EP3481383B1 (ru)
JP (1) JP2019524796A (ru)
KR (1) KR20190039723A (ru)
CN (1) CN109640965A (ru)
AU (1) AU2017308801B2 (ru)
CA (1) CA3031893A1 (ru)
IL (1) IL264467B (ru)
MX (1) MX2019001360A (ru)
NZ (1) NZ750126A (ru)
RU (1) RU2751770C2 (ru)
SG (2) SG10202101247QA (ru)
WO (1) WO2018029545A1 (ru)
ZA (1) ZA201900466B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200116978A (ko) * 2018-02-02 2020-10-13 베링거 인겔하임 인터내셔날 게엠베하 그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체
CN113398112A (zh) * 2021-06-17 2021-09-17 西南医科大学 FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
CN1044364C (zh) * 1993-06-26 1999-07-28 河南师范大学 一种治疗肠炎和溃疡性结肠炎的药物及其制备工艺
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
CN101365428B (zh) * 2006-01-05 2012-08-29 威洛克塞斯药物股份公司 可负载崩解片剂
PT2315740T (pt) * 2008-07-08 2018-01-30 Catabasis Pharmaceuticals Inc Salicilatos acetilados de ácido gordo e suas utilizações
US9248112B2 (en) * 2009-04-06 2016-02-02 Crearene Ltd. Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds
IT1400119B1 (it) * 2010-05-24 2013-05-17 Sofar Spa Nuovi derivati della mesalazina, processo di sintesi ed uso nel trattamento di malattie infiammatorie intestinali.
NZ701832A (en) * 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2014091384A2 (en) * 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9333187B1 (en) * 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
SG11201900588YA (en) 2019-02-27
JP2019524796A (ja) 2019-09-05
RU2019101849A3 (ru) 2020-09-11
EP3481383A1 (en) 2019-05-15
US20220162156A1 (en) 2022-05-26
CN109640965A (zh) 2019-04-16
EP3481383B1 (en) 2023-06-14
US11078154B2 (en) 2021-08-03
NZ750126A (en) 2022-07-01
US20190177267A1 (en) 2019-06-13
KR20190039723A (ko) 2019-04-15
ZA201900466B (en) 2020-06-24
AU2017308801A1 (en) 2019-02-07
AU2017308801B2 (en) 2022-03-10
IL264467B (en) 2021-09-30
WO2018029545A1 (en) 2018-02-15
RU2751770C2 (ru) 2021-07-16
EP3481383A4 (en) 2020-03-18
MX2019001360A (es) 2019-06-03
SG10202101247QA (en) 2021-03-30
IL264467A (en) 2019-02-28
CA3031893A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
RU2490272C2 (ru) Макроциклические ингибиторы серинпротеазы
RU2382026C2 (ru) Аналоги липоксина а4
JP2019517523A (ja) 肝線維症を治療する方法
RU2014139169A (ru) Парентеральные составы для введения макролидных антибиотиков
RU2006141647A (ru) Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
RU2009101150A (ru) Противоопухолевые соединения дигидропиран-2-она
US6417197B1 (en) Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action
RU2007143509A (ru) Производные ацетилена
RU2009101324A (ru) Композиции и способы лечения воспаления слизистой оболочки
RU2010126056A (ru) Органические соединения
RU2007143505A (ru) Производные ацетилена
RU2007143507A (ru) Производные фенилацетилена, обладающие сродством к рецептору mglur 5
CA2873096A1 (en) Compositions and methods for the treatment of inflammatory bowel disease
JP2010505865A5 (ru)
RU2011113967A (ru) Новое производное простагландина i2
RU2019101849A (ru) Композиции и способы лечения синдрома раздраженного кишечника
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2008152751A (ru) Соли тримебутина и n-десметилтримебутина
KR20100100584A (ko) 장질환 치료용 이소소르비드 모노니트레이트 유도체
RU2019100713A (ru) Композиции и способы для лечения рака
RU2010128542A (ru) Производные 3-карбоксипропил-аминотетралина и родственные соединения в качестве антагонистов mu-опиоидного рецептора
RU2014131017A (ru) Хиназолиноновые производные в качестве ингибиторов hcv
RU2008138749A (ru) Производные камптотецина и их применение
RU2019116981A (ru) Композиции и способы лечения желудочно-кишечных полипов